4.2 Review

Therapeutic management of premenstrual syndrome

期刊

EXPERT OPINION ON PHARMACOTHERAPY
卷 11, 期 17, 页码 2879-2889

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2010.509344

关键词

menstrual disorders; oral contraceptives; PMS; premenstrual syndrome; serotonin reuptake inhibitors; treatment

资金

  1. Forest Research
  2. Wyeth
  3. Pfizer
  4. Xanodyne Pharmaceuticals
  5. Eli Lilly
  6. GlaxoSmithKline
  7. Warner-Lambert
  8. Berlex
  9. Solvay Pharmaceuticals

向作者/读者索取更多资源

Importance of the field: Premenstrual syndrome (PMS) is among the most common health problems reported by reproductive-age women. Estimates indicate that up to 25% of women may warrant treatment for the distress or impaired functioning associated with the symptoms. Areas covered in this review: The primary focus of this review is the clinical condition of PMS and randomized, placebo-controlled trials of PMS treatment. A literature search in PubMed was conducted for these topics. The most recent reports of specific treatments in controlled treatment studies and all meta-analyses were selected. What the reader will gain: Reports consistently indicate that serotonergic antidepressants reduce PMS symptoms compared to a placebo. Hormonal treatments are the most widely prescribed medical treatment. Some oral contraceptives and gonadotropin-releasing hormone analogs have demonstrated efficacy, particularly for women who want contraception and PMS symptom control. Numerous non-pharmacologic treatments are utilized, but efficacy is reported only for calcium supplements, Vitex agnus castus (chasteberry), and cognitive-behavioral therapies. Further research to develop new therapies for the 40% of women with PMS who do not respond to the currently available treatments is needed. Take home message: There are treatments with demonstrated efficacy for PMS, and the majority of women can be helped.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据